SLNO — Stock Film
STOCK FILMSCENE 1/11SLNO · $53.01
Stock Expert AI presents
SLNO
Soleno Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Soleno Therapeutics, Inc. A quick introduction.

On the stock market since 2014, it operates in the world of health and science. It has 115 employees. Now — the numbers.

on the stock market since 2014
115 employees
$2.8B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $11 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 11%

This is an established company with proven profits.

THE SALES TREND
The sales picture, year by year.

Red columns mark years that ended in a loss.

$0
2021
$0
2022
$0
2023
$0
2024
$190.4M
2025
Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $302.8M would still be left in the vault — a solid cushion for hard times.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
5 / 8
EXPECTATIONS MET OR BEATEN
5
Aug 2024
Nov 2024
Feb 2025
May 2025
Aug 2025
Nov 2025
Feb 2026
May 2026
5 TIMES IN THE LAST 8 QUARTERS
A mixed scorecard.
THE COUNCIL REVIEW
9

angles, checked one by one.

The 5 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
Heavy investment in the future10/10
WEAK SPOTS
Executives aren’t buying3/10
Heavy bets against the stock3/10
The stock has lost its spark3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 46% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $305.5M in the vault; even if every debt were paid off, $302.8M would remain.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $76.5044% above today’s price.

1
THE RISKS · 1/2
A rich price tag

The company’s market value is 132 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/2
Executives lean toward selling

Over the last 12 months, executives reported 85 sells against just 23 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, SLNO sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: SLNO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film